

## Special Issue

# 2nd Edition of Advances in Vaccine Biomanufacturing Processes

### Message from the Guest Editor

The aim of this Special Issue is to present significant advances made in bioprocessing for the robust, rapid, flexible and cost-efficient manufacturing of vaccines. Contributions on a range of themes are welcome, including process intensification of upstream and downstream operations to improve productivity and increase product yield and purity, the development and application of new process analytical technologies to support process development and analyses of product quality attributes, the design of novel monitoring tools and control strategies to ensure process consistency and performance, the application of new high-throughput technologies and Quality-by-Design approaches for vaccine manufacturing, and devising new cell line platforms, innovative bioreactor designs and downstream processing techniques. Since rational process development and optimization are highly dependent on a good understanding of the complex production steps and interactions between cells and viruses, contributions related to the modeling of cell culture kinetics, as well as the application of systems biology and metabolic engineering approaches, are also welcome.

---

### Guest Editor

Prof. Dr. Olivier Henry  
Department of Chemical Engineering, Polytechnique Montréal,  
Montréal, QC, Canada

---

### Deadline for manuscript submissions

closed (30 June 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/135158](https://mdpi.com/si/135158)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).